We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cytology Brush Test Proves Superior for Mucosal Leishmaniasis

By LabMedica International staff writers
Posted on 20 Dec 2011
A novel, noninvasive, cytology-brush based polymerase chain reaction (PCR) has been developed for the diagnosis of mucosal leishmaniasis (ML). More...


The cytology brush PCR test has been compared with traditional methods of diagnosing such as biopsy with histopathology, which are insensitive and require collection of an invasive diagnostic specimen.

Scientists at the University of Toronto (ON, Canada) working with colleagues in Peru, enrolled 28 patients, of whom 23 fulfilled criteria for a diagnosis of ML. They compared standard invasive procedures including biopsy histopathology, biopsy PCR, and leishmanin skin test (LST) to a novel, noninvasive, cytology-brush based PCR for the diagnosis of ML in Lima (Peru). Consensus reference standard was 2/4 tests positive, and outcome measures were sensitivity and specificity. Leishmania species identification was performed by PCR-based assays of positive specimens.

Two different cytology brushes CerviSoft and Histobrush (Puritan Medical Products; Guilford, ME, USA) were tested and compared with the other tests. Disaggregated tissue and cytology brushes were processed for DNA isolation using the High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany). PCR assays were performed using the HotStar Taq Plus DNA Polymerase kit (QIAGEN; Hilden, Germany).

Subjective tolerability of the CerviSoft brush was superior to that of the Histobrush as it was reported to cause less discomfort and was softer on the mucosa, particularly in the nose. All healthy control volunteers had negative CerviSoft and Histobrush cytology brush PCR. Sensitivity and specificity of biopsy with histopathology were 21.7% and 100%; 69.6% and 100% for LST; 95.7% and 100% for biopsy PCR; and 95.7% and 90% for cytology brush PCR using both CerviSoft and Histobrush cervical cytology brushes. Represented species identified by PCR- Restriction Fragment Length Polymorphism (RFLP) included four L. braziliensis, and three L. peruviana.

The authors concluded that use of commercial grade cytology brush PCR for diagnosis of ML is sensitive, rapid, well tolerated, and carries none of the risks of invasive diagnostic procedures such as biopsy. Further optimization is required for adequate species identification. Further evaluation of this method in field and other settings is warranted. The study was published on October 27, 2011, in the online journal Public Library of Science One.

Related Links:
University of Toronto
Puritan Medical Products



Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.